A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities (“ALFs”), and behavioral health facilities and group homes (collectively “BHFs”). More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, which are our target markets, while the remainder has been generated primarily from residents of skilled nursing facilities (“SNFs”). Additionally, our robust suite of capabilities enables us to serve residents in all types of LTCFs.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 1.4B | 1.4B | 1.2B | 1.0B |
| Net Income | 49M | 49M | -110M | 24M |
| EPS | $0.78 | $0.78 | $-1.77 | $0.38 |
| Free Cash Flow | 87M | 87M | 43M | 70M |
| ROIC | 25.1% | 36.1% | -73.4% | 34.3% |
| Gross Margin | 20.2% | 20.2% | 19.9% | 19.9% |
| Debt/Equity | 0.19 | 0.19 | 0.20 | 1.02 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | 73M | 73M | -63M | 41M |
| Operating Margin | 5.0% | 5.0% | -5.1% | 3.9% |
| ROE | 22.6% | 26.8% | -73.4% | 39.9% |
| Shares Outstanding | 63M | 63M | 62M | 63M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 1.0B | 1.2B | 1.4B | 1.4B |
| Gross Margin | 19.9% | 19.9% | 20.2% | 20.2% |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | 167M | 307M | 220M | 220M |
| EBIT | 41M | -63M | 73M | 73M |
| Op. Margin | 3.9% | -5.1% | 5.0% | 5.0% |
| Net Income | 24M | -110M | 49M | 49M |
| Net Margin | 2.3% | -9.0% | 3.4% | 3.4% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | 34.3% | -73.4% | 36.1% | 25.1% |
| ROE | 39.9% | -73.4% | 26.8% | 22.6% |
| ROA | 8.8% | -34.3% | 13.4% | 11.9% |
| Cash Flow | ||||
| Op. Cash Flow | 71M | 58M | 100M | 100M |
| Free Cash Flow | 70M | 43M | 87M | 87M |
| Owner Earnings | 46M | -93M | 64M | 64M |
| CapEx | 985K | 15M | 13M | 13M |
| Maint. CapEx | 18M | 20M | 22M | 22M |
| Growth CapEx | 0 | 0 | 0 | 0 |
| D&A | 18M | 20M | 22M | 22M |
| CapEx/OCF | N/A | 25.4% | N/A | 13.4% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 55M | 29M | 29M |
| Buyback Yield | N/A | 4.2% | 0.0% | 1.2% |
| Stock-Based Comp | 6.1M | 131M | 14M | 14M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | 59M | 21M | -90M | -25M |
| Cash & Equiv. | 752K | 4.7M | 66M | 66M |
| Long-Term Debt | 19M | N/A | 0 | N/A |
| Debt/Equity | 1.02 | 0.20 | 0.19 | 0.19 |
| Interest Coverage | 14.3 | -19.2 | 109.3 | 109.3 |
| Equity | 60M | 150M | 218M | 218M |
| Total Assets | 271M | 321M | 413M | 413M |
| Total Liabilities | 211M | 171M | 195M | 195M |
| Intangibles | 12M | 15M | 18M | 18M |
| Retained Earnings | N/A | 17M | 66M | 66M |
| Working Capital | -8.4M | 7.9M | 61M | 61M |
| Current Assets | 130M | 152M | 222M | 222M |
| Current Liabilities | 138M | 144M | 161M | 161M |
| Per Share Data | ||||
| EPS | 0.38 | -1.77 | 0.78 | 0.78 |
| Owner EPS | 0.73 | -1.50 | 1.02 | 1.02 |
| Book Value | 0.95 | 2.41 | 3.45 | 3.45 |
| Cash Flow/Share | 1.12 | 0.93 | 1.59 | 1.13 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 63.3M | 62.2M | 63.1M | 63.1M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | 50.6 |
| P/FCF | N/A | 30.5 | N/A | 28.7 |
| EV/EBIT | N/A | N/A | N/A | 33.9 |
| Price/Book | N/A | 9.2 | N/A | 11.4 |
| Price/Sales | N/A | 1.0 | N/A | 1.7 |
| FCF Yield | N/A | 3.3% | N/A | 3.5% |
| Market Cap | N/A | 1.3B | 0 | 2.5B |
| Avg. Price | N/A | 20.48 | 0.00 | 39.49 |
| Year-End Price | N/A | 21.21 | 0.00 | 39.49 |
Guardian Pharmacy Services, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 56.8x vs a median of 30.5x. The company's 5-year average gross margin is 20.0%. Total shareholder yield (buybacks) is 1.2%.
Guardian Pharmacy Services, Inc. (GRDN) has a 5-year average return on invested capital (ROIC) of -1.0%. This is below average and may indicate limited pricing power.
Guardian Pharmacy Services, Inc. (GRDN) has a market capitalization of $2.5B. It is classified as a mid-cap stock.
Guardian Pharmacy Services, Inc. (GRDN) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.17%.
Guardian Pharmacy Services, Inc. (GRDN) operates in the Retail-Drug Stores And Proprietary Stores industry, within the Consumer Cyclical sector.
Guardian Pharmacy Services, Inc. (GRDN) reported annual revenue of $1.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
Guardian Pharmacy Services, Inc. (GRDN) has a net profit margin of 3.4%. This is a modest margin.
Guardian Pharmacy Services, Inc. (GRDN) generated $87 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Guardian Pharmacy Services, Inc. (GRDN) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
Guardian Pharmacy Services, Inc. (GRDN) reported earnings per share (EPS) of $0.78 in its most recent fiscal year.
Guardian Pharmacy Services, Inc. (GRDN) has a return on equity (ROE) of 26.8%. This indicates the company generates strong returns for shareholders.
Guardian Pharmacy Services, Inc. (GRDN) has a 5-year average gross margin of 20.0%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 3 years of financial data for Guardian Pharmacy Services, Inc. (GRDN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Guardian Pharmacy Services, Inc. (GRDN) has a book value per share of $3.45, based on its most recent annual SEC filing.